The market underestimates TGTX's ability to expand Briumvi's market share in MS due to entrenched competitors, ignoring rapid uptake among community neurologists and payer access improvements. Investors are anchored to past commercialization missteps, missing the inflection point in prescription growth and margin leverage.
Bear
$18
-46%
30%
Base
$32
-5%
50%
Bull
$50
+49%
20%
Catalysts
Q2/Q3 prescription growth exceeding consensus
Major payer coverage expansions or formulary wins
Positive real-world efficacy or safety data for Briumvi
Risk Factors
Slower-than-expected Briumvi adoption due to competitive dynamics
Reimbursement or pricing pushback from payers
Single-asset risk with no pipeline diversification
Key Debates
TGTX sustains 100%+ revenue growth through Q4 2024, driven by Briumvi market penetration.
TGTX Fwd P/E expands to 30x by H2 2024 on improving operating leverage.
TGTX stock reaches $49.50 analyst target by Q3 2024 on Briumvi outperformance.
Recent Daily Analysis
— The glaring paradox in TG Therapeutics' data—a perfect 100/100 Quality score versus a deeply negative -280% DCF gap—points to a specific flaw in analyst modeling: an overestimation of long-term SG&A expenses. We hypothesize that consensus models are pricing the company as if it must maintain peak launch-level marketing spend indefinitely. This ignores the durable moat created by its drug's best-in-class clinical profile, which should allow for significant operating leverage as sales mature. If the next earnings call shows SG&A as a percentage of revenue declining even slightly, it will invalidate the core assumption behind the negative DCF, forcing a rapid upward re-rating of its terminal value.